GLEEVEC
FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)
Pressure score
78
Momentum score
64
Why This Matters
AstraZeneca is a regulatory competitive threat because recent agency-facing activity on GLEEVEC in Oncology · Tyrosine Kinase Inhibitor may reset approval benchmarks and timeline expectations for Novartis.
Competitive Assessment
- Threat type
- regulatory competitor
- Development stage
- Approved
- Stage gap
- Competitor is at a comparable development stage, indicating head-to-head race dynamics.
- Market share risk
- Approved competitor status elevates immediate revenue and share risk.
Strategic Action
Align with signal posture: monitor. Monitor regulatory competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)
Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor · Regulatory Approval · This approval strengthens AstraZeneca's position in the diabetes market, particularly against competitors offering similar combination therapies.
Source: Humanexa Signals
No public source document URL on file.
Related Signal
FDA Accepts Supplement Application for GLEEVEC (Imatinib Mesylate)
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 2
Lilly
1 competitive finding
Top program: GLEEVEC
- Pressure
- 79
- Momentum
- 51
- Threat
- regulatory competitor
- Stage
- Approved
79LillyHighGLEEVEC·Approved
AstraZeneca
1 competitive finding
Top program: GLEEVEC
- Pressure
- 78
- Momentum
- 64
- Threat
- regulatory competitor
- Stage
- Approved
78AstraZenecaHighGLEEVEC·Approved